Self-Organization of Polyurethane Ionomers Based on Organophosphorus-Branched Polyols.

Based on organophosphorus branched polyols (AEPAs) synthesized using triethanolamine (TEOA), -phosphoric acid (OPA), and polyoxyethylene glycol with MW = 400 (PEG), vapor-permeable polyurethane ionomers (AEPA-PEG-PUs) were obtained. During the synthesis of AEPAs, the reaction of the OPA etherification with polyoxyethylene glycol was studied in a wide temperature range and at different molar ratios of the starting components. It turned out that OPA simultaneously undergoes a catalytically activated etherification reaction with triethanolamine and PEG.

Organophosphorus Polyurethane Ionomers as Water Vapor Permeable and Pervaporation Membranes.

Organophosphorus polyurethane ionomers (AEPA-PU) based on aminoethers of -phosphoric acid (AEPA) were obtained and studied as pervaporation membrane materials for separating isopropanol/water mixtures. The regularities of the change in the water vapor permeability of AEPA-PU were also investigated. It has been established that an increase of solute content in the composition of the urethane-forming system and the content of ionogenic groups in AEPA leads to a noticeable increase in the vapor permeability of the resulting film materials.

[Recombinant activated factor VII use for the bleeding implications prevention during central venous catheterization in pediatric patients with acute leucosis and thrombocytopenia].

Unlabelled: Research objective was to develop an algorithm of the recombinant activated Factor VII (rFVIIa) prophylactic use for the bleeding implications prevention during central venous catheterization in Pediatric patients with acute leucosis and thrombocytopenia.

Methods: 30 Pediatric patients with acute leucosis and thrombocytopenia received rFVIIa 30-120 microg kg(-1) before the internal jugular vein catheterization with ultrasound control. Comparative group 1 included 39 Pediatric patients without preventive haemostatic treatment; comparative group 2 included 30 patients received platelet concentrate.

[Use of amixin in the therapy and prevention of some viral infections].

The trial of oral interferon inductor amixin for effectiveness in chronic viral hepatitis (CVH) and hemorrhagic fever with renal syndrome (HFRS) has shown that amixin in CVH improved general condition of the patients, removed yellowness of the skin and sclera, normalized activity of aminotransferases and blood bilirubin level. Virus replication was stopped in 25 and 1.6% in CVHB and CVGC, respectively.